目的 研究肝蘇顆粒聯(lián)合替比夫定片治療慢性乙型肝炎的臨床療效。方法 選取2014年1月-2017年2月四川大學(xué)華西醫(yī)院收治的慢性乙型肝炎患者120例為研究對(duì)象，隨機(jī)將所有患者分為對(duì)照組和治療組，每組各60例。對(duì)照組口服替比夫定片，1片/次，1次/d；治療組在對(duì)照組治療的基礎(chǔ)上口服肝蘇顆粒，1袋/次，3次/d。兩組患者均持續(xù)治療48周。觀察兩組的臨床療效，比較兩組的血清乙肝標(biāo)志物和肝功能指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.67%、95.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組和治療組乙肝表面抗原（HBsAg）轉(zhuǎn)陰率分別為25.00%、61.67%，乙肝病毒的脫氧核糖核酸（HBV-DNA）轉(zhuǎn)陰率分別為31.67%、55.00%，兩組比較差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清天門冬氨酸氨基轉(zhuǎn)氨酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）、谷氨酰轉(zhuǎn)肽酶（GGT）和總膽紅素（TBIL）水平均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組肝功能指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 肝蘇顆粒聯(lián)合替比夫定片治療慢性乙型肝炎具有較好的臨床療效，能提高HBsAg轉(zhuǎn)陰率和HBV-DNA轉(zhuǎn)陰率，改善患者肝功能，安全性較高，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To study the clinical effect of Gansu Granules combined with Telbivudine Tablets in treatment of chronic hepatitis B. Methods Patients (120 cases) with chronic hepatitis B in West China Hospital of Sichuan University from January 2014 to February 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Telbivudine Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Gansu Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 48 weeks. After treatment, the clinical efficacies were evaluated, and serum hepatitis B markers and liver function indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 95.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the negative rates of HBsAg in the control and treatment groups were 25.00% and 61.67%, respectively, and the negative rates of HBV-DNA in the control and treatment groups were 31.67% and 55.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of AST, ALT, GGT, and TBIL in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the liver function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Gansu Granules combined with Telbivudine Tablets has clinical curative effect in treatment of chronic hepatitis B, can increase the negative rates of HBsAg and HBV-DNA, improve live function, which has a certain clinical application value.